Merck Sharp + Dohme Corp.

Agenus Inc.

Merck Sharpe & Dohme Corp.

Barbara Joyce-Shaikh

Andrea Claudia Schuster

Kornelia Schultze

Luis A Zuniga

Daniel J Cua

Milan Blanusa

Yi Heng Chen

Holly Cherwinski

Adele Wang

Joseph H Phillips

Drake LaFace

Douglas C Wilson

Cristina M Tato

Daniel Cua

The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.

Anti-ILT4 antibodies and antigen-binding fragments

The present invention provides antibodies and antigen-binding fragments thereof that bind PI16 and block binding of ILT3 to PI16.

P116 antibodies

The present invention provides antibodies and antigen-binding fragments thereof that bind ILT3, ILT3 ligand (i.e., PI16) or a complex between ILT3 and the ILT3 ligand. Methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding are also provided.

ILT3 ligand

The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.

MDL-1 ligand

The present invention provides methods of using PILR&#x3b1; agonists, or PILR&#x3b2; antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation.

Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-&#x3b1;

Growing community of inventors

San Jose, CA, United States of America

Barbara Joyce-Shaikh